Pfizer taps Cecile Guegan, an internal executive, as CFO after Dave Denton’s August exit

Pfizer has named Cecile Guegan as its chief financial officer, according to a report citing the company’s internal move to fill a top finance role. The appointment makes Guegan the successor to Dave Denton, who left the CFO position in August, leaving the company to recalibrate leadership in its finance function.

The selection of Guegan reflects Pfizer’s preference for internal succession planning. The report characterizes Guegan as an insider promoted into the CFO role, rather than naming an outside candidate. Pfizer did not, in the cited post, lay out additional details such as the specific scope of the transition or whether the hiring process included external candidates.

Denton’s departure in August, described in the report as the triggering event for the CFO change, highlights a continuing churn in executive leadership that often accompanies major strategic and portfolio decisions in large drugmakers. While the post identifies the timing of Denton’s exit, it does not provide additional information in the excerpted material about the circumstances of his departure or interim finance arrangements prior to the new appointment.

As CFO, Guegan is expected to oversee Pfizer’s financial strategy and reporting, including capital allocation decisions that can affect pipeline development, manufacturing and supply commitments, and cost controls. The role also typically includes oversight of investor communications and financial planning, particularly for a company managing multiple late-stage assets and an active pipeline portfolio. The cited report does not specify which financial priorities Pfizer is emphasizing now.